ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company
He describes the different profile of degraders vs small molecules, and highlights BeiGene's programs in BTK, EGFR, IRAK4, and others. Plus ASH data for Brukinsa and a BCL2, and how BeiGene's investments in global scale are bearing fruition.